A number of member states want the European Commission’s competences in health and pharma policy to be upgraded in order to face more effectively the rising challenges in the field, Greek health minister Andreas Ksanthos told EURACTIV.com in an interview.
The next European Commission should focus on the bloc’s role in the global context of innovation, as China is “decisive” about creating a reliable framework for intellectual property and connecting biotech start-ups and digital companies, EFPIA’s President Stefan Oschmann told EURACTIV.com in an interview.
Experts are asking for a more collaborative approach in EU healthcare and greater involvement of the European Commission in order to face rising challenges and put patients at the core of decision-making.
The European Union should not create an environment more favourable to generics compared to the innovative pharmaceuticals, as it risks weakening Europe’s overall global strength in pharmaceuticals and in research, Professor Adrian Towse told EURACTIV.com in an interview.
The Commission’s upcoming proposal on Health Technology Assessment (HTA) will focus on clinical aspects and leave member states to decide on economic or ethical parts, a European Commission spokesperson told EURACTIV.com.
Without strong incentives to spur continued investment in medical innovation, we cannot hope to ensure the sustainability of European healthcare systems and fulfil the promise of our great union, writes Jan Fischer.